FDA Approves First Gene Therapy for Genetic Hearing Loss

Otarmeni (lunsotogene parvec-cwha) is the first FDA-cleared gene therapy that replaces a defective hearing-loss gene via a dual AAV vector — a one-time treatment for patients with mutations in OTOF, a gene responsible for roughly 2-8% of congenital deafness. The technical hook for this reader: dual-AAV is needed because OTOF is too large to fit in a single adeno-associated-virus capsid, a packaging limit that has blocked gene therapy for most large genes. Lead with what the dual-vector approach unlocks for other large-gene disorders (Duchenne, Stargardt) — not just the hearing-loss milestone.